Additionally, VMTB reviewers avoided recommending the off-label use of single agent MEK inhibitors, CDK4/6 inhibitors and mTOR inhibitors, in certain cancer types (despite the fact that these recommendations were routinely listed in the patient’s laboratory-provided reports), due to the lack of sufficient clinical evidence. The gene discussed is CDK4; the disease is cancer.